Zobrazeno 1 - 10
of 504
pro vyhledávání: '"YUKITO ICHINOSE"'
Autor:
Hideo Saka, Chiyoe Kitagawa, Yukito Ichinose, Mitsuhiro Takenoyama, Hidenori Ibata, Tatsuo Kato, Koji Takami, Motohiro Yamashita, Tadashi Maeda, Sadanori Takeo, Hitoshi Ueda, Kan Okabayashi, Seiji Nagashima, Tadayuki Oka, Hidenori Kouso, Seiichi Fukuyama, Kentaro Yoshimoto, Mototsugu Shimokawa, Akiko M. Saito, Suminobu Ito
Publikováno v:
Trials, Vol 18, Iss 1, Pp 1-7 (2017)
Abstract Background As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect
Externí odkaz:
https://doaj.org/article/478109fb6b444fdb99397dbffb2a11cf
Autor:
Masaru Watanabe, Tomoya Kawaguchi, Shun-ichi Isa, Masahiko Ando, Akihiro Tamiya, Akihito Kubo, Hideo Saka, Sadanori Takeo, Hirofumi Adachi, Tsutomu Tagawa, Osamu Kawashima, Motohiro Yamashita, Kazuhiko Kataoka, Yukito Ichinose, Yukiyasu Takeuchi, Katsuya Watanabe, Akihide Matsumura, Yasuhiro Koh
Publikováno v:
EBioMedicine, Vol 21, Iss C, Pp 86-93 (2017)
Epidermal growth factor receptor (EGFR) mutations have been used as the strongest predictor of effectiveness of treatment with EGFR tyrosine kinase inhibitors (TKIs). Three most common EGFR mutations (L858R, exon 19 deletion, and T790M) are known to
Externí odkaz:
https://doaj.org/article/38c362f4c73e4f60970434713501eaf5
Autor:
Yasuhiro Koh, Akihide Matsumura, Kazuhiro Sakamoto, Yukiyasu Takeuchi, Yukito Ichinose, Kazuhiko Kataoka, Motohiro Yamashita, Seiichi Kakegawa, Tsutomu Tagawa, Hirofumi Adachi, Sadanori Takeo, Hideo Saka, Akihito Kubo, Akihiro Tamiya, Masahiko Ando, Shun-ichi Isa, Tomoya Kawaguchi, Masaru Watanabe
Supplementary Figures S1-8. Figure S1: Flowchart for mutation call. Figure S2: Quantification of performance of ddPCR analysis for EGFR T790M mutation. Figure S3: Analytical sensitivity of 0.001% for the ddPCR assay. Figure S4: Determination of false
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4242036600537831c53f664f345297d5
https://doi.org/10.1158/1078-0432.22456137.v1
https://doi.org/10.1158/1078-0432.22456137.v1
Autor:
Yasuhiro Koh, Akihide Matsumura, Kazuhiro Sakamoto, Yukiyasu Takeuchi, Yukito Ichinose, Kazuhiko Kataoka, Motohiro Yamashita, Seiichi Kakegawa, Tsutomu Tagawa, Hirofumi Adachi, Sadanori Takeo, Hideo Saka, Akihito Kubo, Akihiro Tamiya, Masahiko Ando, Shun-ichi Isa, Tomoya Kawaguchi, Masaru Watanabe
Purpose: The resistance to the EGFR tyrosine kinase inhibitors (TKI) is a major concern in non–small cell lung cancer (NSCLC) treatment. T790M mutation in EGFR accounts for nearly 50% of the acquired resistance to EGFR-TKIs. Earlier studies suggest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35b3ad8790d0f4439ce3f54024f02594
https://doi.org/10.1158/1078-0432.c.6523212.v1
https://doi.org/10.1158/1078-0432.c.6523212.v1
Autor:
Yasuhiro Koh, Akihide Matsumura, Kazuhiro Sakamoto, Yukiyasu Takeuchi, Yukito Ichinose, Kazuhiko Kataoka, Motohiro Yamashita, Seiichi Kakegawa, Tsutomu Tagawa, Hirofumi Adachi, Sadanori Takeo, Hideo Saka, Akihito Kubo, Akihiro Tamiya, Masahiko Ando, Shun-ichi Isa, Tomoya Kawaguchi, Masaru Watanabe
Supplementary Materials and Methods, Reference and Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cca6562ace6fa0272ed1b5b35964ddd
https://doi.org/10.1158/1078-0432.22456140.v1
https://doi.org/10.1158/1078-0432.22456140.v1
Autor:
Yasuhiro Koh, Akihide Matsumura, Kazuhiro Sakamoto, Yukiyasu Takeuchi, Yukito Ichinose, Kazuhiko Kataoka, Motohiro Yamashita, Seiichi Kakegawa, Tsutomu Tagawa, Hirofumi Adachi, Sadanori Takeo, Hideo Saka, Akihito Kubo, Akihiro Tamiya, Masahiko Ando, Shun-ichi Isa, Tomoya Kawaguchi, Masaru Watanabe
Supplementary Tables S1-5. Table S1: Primers and probes used for droplet digital PCR (ddPCR). Table S2: Determination of the limit of blank (LOB) from wild-type control DNA, normal human genomic DNA, and EGFR wild-type A549 genomic DNA. Table S3: Det
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::520406ecc177aca83747293358d78716
https://doi.org/10.1158/1078-0432.22456134.v1
https://doi.org/10.1158/1078-0432.22456134.v1
Autor:
Masafumi Yamaguchi, Fumihiko Hirai, Kenichi Taguchi, Ryo Toyozawa, Makoto Edagawa, Shinichiro Shimamatsu, Kaname Nosaki, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose
Publikováno v:
Surgical Case Reports, Vol 3, Iss 1, Pp 1-2 (2017)
Abstract Pure ground-glass opacity nodules (p-GGN) on high-resolution computed tomography (HRCT) generally have been considering typically associated with adenocarcinoma with less invasive nature. We herein reported a patient presenting focal p-GGN o
Externí odkaz:
https://doaj.org/article/24224da709da423d8b16b4f74998ed7e
Autor:
Hiroshi Mukae, Minoru Fukuda, Taishi Harada, Takashi Seto, Koichi Takayama, Takeshi Kitazaki, Takaya Ikeda, Daiki Ogawara, Midori Shimada, Isamu Okamoto, Riichiroh Maruyama, Noriaki Nakagaki, Junji Kishimoto, Masao Ichiki, Noriyuki Ebi, Yukito Ichinose, Kenji Sugio
Publikováno v:
Lung Cancer. 132:1-8
Objectives: To evaluate the efficacy and safety, we conducted a randomized phase II study of pemetrexed (Pem) versus Pem + bevacizumab (Bev) for elderly patients with non-squamous non-small cell lung cancer (NSqNSCLC). Patients and methods: The eligi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0362d3a4fdaa787ea6b426f322dab356
https://nagasaki-u.repo.nii.ac.jp/records/1787
https://nagasaki-u.repo.nii.ac.jp/records/1787
Autor:
Katsuyuki Kiura, Fumio Imamura, Koji Takeda, Kazuhiko Nakagawa, Satoshi Morita, Hideo Saka, Hiroshi Sakai, Koichi Goto, Akihiko Gemma, Tomohide Tamura, Toshiaki Takahashi, Masato Shingyoji, Shunichi Sugawara, Akira Inoue, Makoto Maemondo, Takashi Seto, Yuichiro Ohe, Hiroshi Nokihara, Isamu Okamoto, Makoto Nishio, Yukito Ichinose, Nobuyuki Yamamoto
Publikováno v:
International Journal of Clinical Oncology. 24:485-493
The East Asia S-1 Trial in Lung Cancer (EAST-LC) was a randomized phase III study conducted in East Asia that demonstrated the non-inferiority of S-1 to docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Here,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bd6a804c8cf563bc0f734f601da6017
https://doi.org/10.1007/s10147-019-01396-z
https://doi.org/10.1007/s10147-019-01396-z
Autor:
Akiko Saito, Masao Ichiki, Noriaki Sukoh, Chiyoe Kitagawa, Akiko Kada, Masahide Mori, Yukito Ichinose
Publikováno v:
In Vivo. 33:477-482
Background/aim A phase II trial was conducted to assess the efficacy and safety of gefitinib plus bevacizumab for EGFR mutation-positive non-small cell lung cancer (NSCLC). Patients and methods Patients were randomly assigned to receive either gefiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6c108173ae945b835dcf1eac372b6ca
https://doi.org/10.21873/invivo.11498
https://doi.org/10.21873/invivo.11498